News Archives | Future Medicine India

News

41 active cases of COVID-19 reported in India

Out of a total of 44 positive cases of COVID-19 which have been reported from India, 41 of the cases are active as on 10th March 2020, informs Ministry of Health and Family Welfare (MoHFW).

FM News Network
Read More..

Osilodrostat approved for treating Cushing’s disease

Norvatis has received US FDA approval for osilodrostat (Isturisa) oral tablets in treating adults with Cushing’s disease who cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.

Six in ten women in India have low haemoglobin levels: Metropolis Healthcare

Six in ten women in India have low haemoglobin levels, reported Metropolis Healthcare based on their recent study including 17,00,000 samples obtained from 36 cities in the country.

FM News Network

Government will soon add around 4,000 Jan Aushadhi stores in India

The government will soon add around 4,000 Jan Aushadhi stores in India, taking their numbers to 10,000, said the Union Minister for Chemicals and Fertilizers, D V Sadananda Gowda.

FM News Network

Medical device makers plea for predictive tariff policy to promote domestic production

Medical device makers urged for a predictive nominal tariff protection policy to encourage ‘Make in India’ and reduce the dependency of imports which currently accounts for 80 – 90% of the domestic requirement.

FM News Network

India-developed saroglitazar gets DCGI approval to treat NASH

The Drug Controller General of India (DCGI) has granted approval for saroglitazar to treat non-cirrhotic non-alcoholic steato hepatitis (NASH) in India, announced Zydus Cadila.

FM News Network

EMA panel recommends brigatinib to treat ALK+ lung cancer

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of brigatinib (Alunbrig) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

FM News Network